Myeloma Risk Profile

There are 2 papers on Myeloma Risk Profile in aging research: 1 observational study in people, 1 review.

Biomarker

2 papers study it3 findings

See all 2 papers on Myeloma Risk Profile

“There was a trend for a shorter median OS in the frail subgroup but without a statistical significance: (frail vs. intermediate or fit): (46 months vs. not reached, HR: 1.94, 95% CI 0.89-4.2, p = 0.094).”
Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patientsPloS one2022doi:10.1371/journal.pone.0262388
  • Humans1

Effects

1

Multiple myeloma

no changein humans1HR 0.99

1 study
  1. Myeloma Risk Profile was not clearly linked with multiple myeloma in humans (elderly newly diagnosed myeloma treated with VCD) (11.8 vs. 9.9 months, HR: 0.99, 95% CI: 0.61-1.61, P = 0.982).

    “There was no difference in median PFS between subgroups: (frail vs. intermediate or fit): (11.8 vs. 9.9 months, HR: 0.99, 95% CI: 0.61-1.61, P = 0.982).”

    Humanselderly newly diagnosed myeloma treated with VCDn = 100

    Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients

    PloS one

More on Multiple myeloma

Associations

2

Adverse events

upin humans1

1 study
  1. Myeloma Risk Profile is associated with adverse events in humans (elderly newly diagnosed myeloma treated with VCD) (85.5% vs. 71.1%).

    “This cohort demonstrated a higher incidence rate of AEs in frail patients compared to those in the intermediate or fit group: patients with at least one any grade toxicity (85.5% vs. 71.1%)”

    Humanselderly newly diagnosed myeloma treated with VCDn = 100

    Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients

    PloS one

Mortality

no changein humans1HR 1.94

1 study
  1. Myeloma Risk Profile is associated with mortality in humans (elderly newly diagnosed myeloma treated with VCD) (46 months vs. not reached, HR: 1.94, 95% CI 0.89-4.2, p = 0.094).

    “There was a trend for a shorter median OS in the frail subgroup but without a statistical significance: (frail vs. intermediate or fit): (46 months vs. not reached, HR: 1.94, 95% CI 0.89-4.2, p = 0.094).”

    Humanselderly newly diagnosed myeloma treated with VCDn = 100

    Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients

    PloS one

Latest